With the shift from volume to value in the healthcare marketplace, pharma manufacturers have entered into a variety of Real World Data (RWD) collaborations to generate better evidence of the effectiveness, benefits and harms of different treatment options.
eyeforpharma studied 61 of these connections and, in speaking with RWD leaders, investigated the 10 industry-leading collaborations between pharma, payers, providers and other stakeholders in this new, complementary report.
For your free download of the 20-page analysis click here: http://www.eyeforpharma.com/real-world-data-and-health-outcomes/content-paper.php
The report will allow you to:
· Understand the type and scope of current partnerships, and the objectives of each side
· Discover what exactly can be done to fasten the strength of such collaborations
· Leverage lessons learnt from the 61 different connections that we examined
You’ll receive insights into collaborations between Eli Lilly/ T1D exchange, Deloitte/ Intermountain, Humana/ Astellas, GSK/ Community Care of North Carolina, Genentech/ PatientsLikeMe, IBM/ Premier, as well as multi-stakeholder approaches through Optum Labs, EMIF, OMOP and Merck’s M2i2.
Get access to the exclusive insights and pick up your copy of our latest report now.
Real World Evidence & Data Partnerships Summit eyeforpharma.com
Real World Evidence by EyeforPharma is the pharmaceutical industry’s leading conference on real world evidence – bringing together pharma, payers, agencies and thought leaders to tackle data challenges and improving patient health outcomes.